ThromboVision Inc., a biomedical diagnostics company, has commenced clinical trials of its ThromboGuide (T-Guide) Platelet Function Monitor. Four main research institutes have initiated enrollment and data collection. ThromboVision’s President and CEO, Edward R. Teitel, said that the 510(k) application to the FDA is expected in early 2008.

The T-Guide(R) consists of a disposable test kit and a point-of-care base unit. The system will help physicians improve their cardiac patients’ lives by individualizing antiplatelet therapy that they use to prevent heart attacks, strokes and stent occlusions.